Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease

Ma,Qing‑Hua; Jiang,Liu‑Fang; Mao,Jian‑Liang; Xu,Wen‑Xin; Huang,Min

doi:10.3892/mmr.2017.8289

Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease

Authors:
- Qing‑Hua Ma
- Liu‑Fang Jiang
- Jian‑Liang Mao
- Wen‑Xin Xu
- Min Huang
View Affiliations

Affiliations: Department of Preventive Health, The 3rd People's Hospital of Xiangcheng District, Suzhou, Jiangsu 215134, P.R. China, Department of Basic Courses, Computer Teaching and Research Section, Suzhou Vocational Health College, Suzhou, Jiangsu 215009, P.R. China, Department of General Medicine, Suzhou Municipal Hospital, Suzhou, Jiangsu 215001, P.R. China
Published online on: December 18, 2017 https://doi.org/10.3892/mmr.2017.8289
Pages: 4113-4119

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetes has been identified to be a risk factor for Alzheimer's disease (AD). Vildagliptin, a novel oral hypoglycemic agent, has been demonstrated to exert protective effects on the pancreas and cardiovascular system. The present study examined the potential protective effects of vildagliptin on neurons in an AD rat model. Treatment with vildagliptin improved memory deficits and decreased neuronal apoptosis in the hippocampus. The expression levels of B cell lymphoma 2 (Bcl‑2) were increased, and the expression levels of caspase‑3, Bcl‑2 associated X protein and AD‑associated proteins were decreased in the hippocampus following treatment with vildagliptin. Additionally, the AD model‑induced decrease in phosphorylated (p) protein kinase B (p‑Akt), p‑glycogen synthase kinase 3β (p‑GSK3β), post‑synaptic density 95 and synaptophysin expression was reversed. These results indicate that vildagliptin administration exerts a protective effect against cognitive deficits by reducing tau phosphorylation and increasing the expression of proteins associated with synaptic plasticity in the hippocampus. Targeting of the Akt/GSK3β signaling pathway may be a key mechanism in preventing the disease progression of AD.

View Figures

View References

1	Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S and Van der Flier WM: Alzheimer's disease. Lancet. 388:505–517. 2016. View Article : Google Scholar : PubMed/NCBI
2	Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W and Ferri CP: The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement. 9:63–75. 2013. View Article : Google Scholar : PubMed/NCBI
3	Li X, Bao X and Wang R: Neurogenesis-based epigenetic therapeutics for Alzheimer's disease. Mol Med Rep. 14:1043–1053. 2016. View Article : Google Scholar : PubMed/NCBI
4	Chen PY, Tsai CT, Ou CY, Hsu WT, Jhuo MD, Wu CH, Shih TC, Cheng TH and Chung JG: Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution. Mol Med Rep. 5:1043–1048. 2012. View Article : Google Scholar : PubMed/NCBI
5	Henry W, Querfurth HW and LaFerla FM: Mechanisms of disease Alzheimer's disease. New Engl J Med. 362:329–344. 2010. View Article : Google Scholar : PubMed/NCBI
6	Zuroff L, Daley D, Black KL and Koronyo-Hamaoui M: Clearance of cerebral Aβ in Alzheimer's disease: Reassessing the role of microglia and monocytes. Cell Mol Life Sci. 74:2167–2201. 2017. View Article : Google Scholar : PubMed/NCBI
7	Kepp KP: Bioinorganic chemistry of Alzheimer's disease. Chem Rev. 112:5193–5239. 2012. View Article : Google Scholar : PubMed/NCBI
8	Patrone C, Eriksson O and Lindholm D: Diabetes drugs and neurological disorders: New views and therapeutic possibilities. Lancet Diabetes Endocrinol. 2:256–262. 2014. View Article : Google Scholar : PubMed/NCBI
9	Palleria C, Leporini C, Maida F, Succurro E, De Sarro G, Arturi F and Russo E: Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes. Front Neuroendocrinol. 42:76–92. 2016. View Article : Google Scholar : PubMed/NCBI
10	Darsalia V, Olverling A, Larsson M, Mansouri S, Nathanson D, Nyström T, Klein T, Sjöholm Å and Patrone C: Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regul Pept 190–191. 1–31. 2014.
11	Nassar NN, Al-Shorbagy MY, Arab HH and Abdallah DM: Saxagliptin: A novel antiparkinsonian approach. Neuropharmacology. 89:308–317. 2015. View Article : Google Scholar : PubMed/NCBI
12	Matteucci E and Giampietro O: Mechanisms of Neurodegeration in Type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors. Curr Med Chem. 22:1573–1581. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zheng T, Qin L, Chen B, Hu X, Zhang X, Liu Y, Liu H, Qin S, Li G and Li Q: Association of plasma DPP4 activity with mild cognitive impairment in elderly patients with type 2 diabetes: results from the GDMD study in China. Diabetes Care. 39:1594–1601. 2016. View Article : Google Scholar : PubMed/NCBI
14	Kosaraju J, Murthy V, Khatwal RB, Dubala A, Chinni S, Muthureddy Nataraj SK and Basavan D: Vildagliptin: An anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J Pharm Pharmacol. 65:1773–1784. 2013. View Article : Google Scholar : PubMed/NCBI
15	Brion JP, Fraser H, Flament-Durand J and Dickinson AG: Amyloid scrapie plaques in mice and Alzheimer senile plaques, share common antigens with tau, a microtubule-associated protein. Neurosci Lett. 78:113–118. 1987. View Article : Google Scholar : PubMed/NCBI
16	Gonzalez B, Abud EM, Abud AM, Poon WW and Gylys KH: Tau spread, apolipoprotein E, inflammation and more: Rapidly evolving basic science in alzheimer disease. Neurol Clin. 35:175–190. 2017. View Article : Google Scholar : PubMed/NCBI
17	Storr T: Ligand design in medicinal inorganic chemistry. John Wiley & Sons; New York, NY: 2014, View Article : Google Scholar : PubMed/NCBI
18	Jakobroetne R and Jacobsen H: Alzheimer's disease: From pathology to therapeutic approaches. Angew Chem Int Ed Enge. 48:3030–3059. 2009. View Article : Google Scholar
19	Pintana H, Apaijai N, Chattipakorn N and Chattipakorn SC: DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J Endocrinol. 218:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
20	Gault VA, Lennox R and Flatt PR: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes Metab. 17:403–413. 2015. View Article : Google Scholar : PubMed/NCBI
21	D'Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F and Paolisso G: Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol. 45:202–207. 2010. View Article : Google Scholar : PubMed/NCBI
22	Pintana H, Tanajak P, Pratchayasakul W, Sa-Nguanmoo P, Chunchai T, Satjaritanun P, Leelarphat L, Chattipakorn N and Chattipakorn SC: Energy restriction combined with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in obese male rats. Br J Nutr. 1–9. 2016.PubMed/NCBI
23	El Batsh MM, El Batch MM, Shafik NM and Younos IH: Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats. Eur J Pharmacol. 769:297–305. 2015. View Article : Google Scholar : PubMed/NCBI
24	Gao C, Hölscher C, Liu Y and Li L: GSK3: A key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci. 23:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
25	Yu T and Lin W: Small-molecule GSK-3 inhibitor rescued apoptosis and neurodegeneration in anesthetics-injured dorsal root ganglion neurons. Biomed Pharmacother. 84:395–402. 2016. View Article : Google Scholar : PubMed/NCBI
26	Fan R, Li X, Gu X, Chan JC and Xu G: Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: Potential involvement of AKT and mitochondria biogenesis. Diabetes Obes Metab. 12:815–824. 2010. View Article : Google Scholar : PubMed/NCBI
27	Savelieff MG, Lee S, Liu Y and Lim MH: Untangling amyloid-β, tau, and metals in Alzheimer's disease. Acs Chem Biol. 8:856–865. 2013. View Article : Google Scholar : PubMed/NCBI
28	Nadezhdin KD, Bocharova OV, Bocharov EV and Arseniev AS: Structural and dynamic study of the transmembrane domain of the amyloid precursor protein. Acta Naturae. 3:69–76. 2011.PubMed/NCBI
29	Köpke E, Tung YC, Shaikh S, Alonso AC, Iqbal K and Grundke-Iqbal I: Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem. 268:24374–24384. 1993.PubMed/NCBI
30	Braak H, Thal DR, Ghebremedhin E and Del Tredici K: Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol. 70:960–969. 2011. View Article : Google Scholar : PubMed/NCBI
31	Do Carmo S, Crynen G, Paradis T, Reed J, Iulita MF, Ducatenzeiler A, Crawford F and Cuello AC: Hippocampal proteomic analysis reveals distinct pathway deregulation profiles at early and late stages in a rat model of alzheimer's-like amyloid pathology. Mol Neurobiol. May 13–2017.(Epub ahead of print). View Article : Google Scholar
32	Pratley RE, Jauffret-Kamel S, Galbreath E and Holmes D: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 38:423–428. 2006. View Article : Google Scholar : PubMed/NCBI